Multi-centre study designed to reflect routine clinical care in order to assess the persistence on treatment in women with postmenopausal osteoporosis receiving once-monthly ibandronate [ibandronic acid] with a patient support programme versus once weekly alendronate [alendronic acid].
Phase of Trial: Phase IV
Latest Information Update: 18 Sep 2009
At a glance
- Drugs Alendronic acid; Ibandronic acid
- Indications Menopause; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms PERSIST
- 18 Sep 2009 Actual end date (30 Jun 2005) added as reported by ISRCTN: Current Controlled Trials.
- 04 Nov 2005 New trial record.